Literature DB >> 25500011

Hip flexion weakness is associated with impaired mobility in oculopharyngeal muscular dystrophy: a retrospective study with implications for trial design.

Sarah Youssof1, Ronald Schrader2, David Bear3, Leslie Morrison4.   

Abstract

Oculopharyngeal muscular dystrophy (OPMD) is a rare myopathy for which validated outcome measures are lacking, posing a barrier to clinical trials. Our goal was to identify factors associated with impaired mobility in OPMD in order to guide development of surrogate endpoints in future clinical trials. One hundred forty-four individuals with OPMD were included in this retrospective, single-center study. We made novel use of parametric time-to-event analysis to model age at initial use of assistive device for ambulation. We hypothesized that limb weakness and other markers of disease severity are associated with earlier use of assistive devices. 23.6% of individuals (34/144) progressed to use of assistive devices (mean age 66.0 ± 9.6 y). Earlier age at assistive device was associated with hip flexion Medical Research Council grade ≤3 (p <0.0001), earlier disease onset (p <0.0001), and lack of blepharoptosis surgery (p = 0.011). Markers of dysphagia severity were not associated with earlier progression to assistive devices. Our study is the first to show a statistical association between hip flexion weakness and impaired mobility in OPMD, indicating that hip flexion strength could be explored as a surrogate endpoint for use in clinical trials. Since severity of disease features may be discordant within individuals, composite outcome measures are warranted.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Mobility impairment; Natural history; Oculopharyngeal muscular dystrophy; Outcome measures; Time-to-event analysis

Mesh:

Year:  2014        PMID: 25500011      PMCID: PMC4355309          DOI: 10.1016/j.nmd.2014.11.010

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  34 in total

Review 1.  Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies.

Authors:  L J Lesko; A J Atkinson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

2.  Oculopharyngeal muscular dystrophy. A familial disease of late life characterized by dysphagia and progressive ptosis of the evelids.

Authors:  M VICTOR; R HAYES; R D ADAMS
Journal:  N Engl J Med       Date:  1962-12-20       Impact factor: 91.245

3.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  Lancet       Date:  2007-10-20       Impact factor: 79.321

4.  Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity.

Authors:  C E Jackson; R J Barohn; G Gronseth; S Pandya; L Herbelin
Journal:  Muscle Nerve       Date:  2008-04       Impact factor: 3.217

5.  GCG repeats and phenotype in oculopharyngeal muscular dystrophy.

Authors:  T Müller; R Schröder; S Zierz
Journal:  Muscle Nerve       Date:  2001-01       Impact factor: 3.217

6.  Long-term results of cricopharyngeal myotomy in oculopharyngeal muscular dystrophy.

Authors:  Laurent Coiffier; Sophie Périé; Pascal Laforêt; Bruno Eymard; Jean Lacau St Guily
Journal:  Otolaryngol Head Neck Surg       Date:  2006-08       Impact factor: 3.497

7.  Oculopharyngeal muscular dystrophy in Hispanic New Mexicans.

Authors:  M W Becher; L Morrison; L E Davis; W C Maki; M K King; J M Bicknell; B L Reinert; C Bartolo; D G Bear
Journal:  JAMA       Date:  2001-11-21       Impact factor: 56.272

8.  GCG genetic expansions in Italian patients with oculopharyngeal muscular dystrophy.

Authors:  M Mirabella; G Silvestri; G de Rosa; S Di Giovanni; A Di Muzio; A Uncini; P Tonali; S Servidei
Journal:  Neurology       Date:  2000-02-08       Impact factor: 9.910

9.  The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

Authors:  J M Cedarbaum; N Stambler; E Malta; C Fuller; D Hilt; B Thurmond; A Nakanishi
Journal:  J Neurol Sci       Date:  1999-10-31       Impact factor: 3.181

10.  Challenges in drug development for muscle disease: a stakeholders' meeting.

Authors:  Jerry R Mendell; Cristina Csimma; Craig M McDonald; Diana M Escolar; Scott Janis; John D Porter; Sharon E Hesterlee; R Rodney Howell
Journal:  Muscle Nerve       Date:  2007-01       Impact factor: 3.217

View more
  6 in total

1.  Oropharyngeal dysphagia profiles in individuals with oculopharyngeal muscular dystrophy.

Authors:  L C Tabor; E K Plowman; C Romero-Clark; S Youssof
Journal:  Neurogastroenterol Motil       Date:  2017-11-16       Impact factor: 3.598

2.  Novel mouse models of oculopharyngeal muscular dystrophy (OPMD) reveal early onset mitochondrial defects and suggest loss of PABPN1 may contribute to pathology.

Authors:  Katherine E Vest; Brittany L Phillips; Ayan Banerjee; Luciano H Apponi; Eric B Dammer; Weiting Xu; Dinghai Zheng; Julia Yu; Bin Tian; Grace K Pavlath; Anita H Corbett
Journal:  Hum Mol Genet       Date:  2017-09-01       Impact factor: 6.150

3.  Dysphagia-related quality of life in oculopharyngeal muscular dystrophy: Psychometric properties of the SWAL-QOL instrument.

Authors:  Sarah Youssof; Carol Romero-Clark; Teddy Warner; Emily Plowman
Journal:  Muscle Nerve       Date:  2017-02-12       Impact factor: 3.217

4.  The relationship between physical symptoms and health-related quality of life in oculopharyngeal muscular dystrophy.

Authors:  Sarah Youssof
Journal:  Muscle Nerve       Date:  2016-03-01       Impact factor: 3.217

5.  Correlation between the Functional Movement Screen and Hip Mobility in NCAA Division II Athletes.

Authors:  Matthew T Jenkins; Robert Gustitus; Mike Iosia; Taz Kicklighter; Yuichi Sasaki
Journal:  Int J Exerc Sci       Date:  2017-10-01

6.  Longitudinal Assessment of Strength, Functional Capacity, Oropharyngeal Function, and Quality of Life in Oculopharyngeal Muscular Dystrophy.

Authors:  Rosemarie H M J M Kroon; Johanna G Kalf; Bert J M de Swart; Barbara M van der Sluijs; Jeffrey C Glennon; Vered Raz; Baziel G van Engelen; Corinne G C Horlings
Journal:  Neurology       Date:  2021-08-11       Impact factor: 9.910

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.